CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces

The NMD4C is excited to share that network investigators Drs. Gerald Pfeffer, Alexandra King, Kerri Schellenberg, Toshifumi Yokota and Malcolm King have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces, addressing the community needs, and developing clinical knowledge and therapies. Congratulations to the entire team behind this successful grant application! The grant received funding through a CIHR project grant, for a total of $1.3 million over a five-year period.

Leading grant investigators Dr Gerald Pfeffer, Dr Alexandra King and Dr Kerri Schellenberg share that “Our initial study in 2021 established a high prevalence of SBMA in Indigenous populations in Saskatchewan, and we are excited to have the opportunity to continue this work, reaching more individuals from affected communities and together building a more robust understanding of SBMA in the Indigenous populations in Saskatchewan. However, our goal is not only to advance the genetic understanding of the disease, but to also increase communal awareness and knowledge of SBMA and to work together with Indigenous populations to understand how resources and care can be provided to help affected individuals and communities.”

Project Summary:

Spinal-bulbar muscular atrophy (SBMA) is a rare adult-onset genetic disease that affects nerves and muscles causing weakness affecting the face and neck, arms and legs, and muscles of breathing, and also affects other organs such as the heart, pancreas, liver, sensory, and reproductive systems.

This interdisciplinary study will build on a past pilot study from the team that showed Indigenous people in Saskatchewan have the highest prevalence of SBMA in the world, with genetic studies showing this prevalence being due to a founder effect meaning that there is a common ancestor with this condition, and that the mutation has been passed on over time. The study team will build on these preliminary results and perform a comprehensive study of SBMA, building and extending existing connections to affected communities, bring attention to the resiliency of Indigenous people with SBMA with a photovoice study, and highlight the needs of the SBMA community.

Throughout, the team will engage with communities to determine whether additional resources and supports can be provided to help manage this chronic health condition and determine how best to provide education and other support.

The study team seeks to collaborate with other neuromuscular specialists across Canada to aid in identifying individuals who have SBMA and invite them to participate in the study. Those who consent to participate will be asked to provide clinical information and the option to provide blood samples for further study. This will let the team test potential future therapies for SBMA. If you are a neuromuscular specialist interested in helping with recruitment for the study, please contact Dr Gerald Pfeffer at .

Full Grant Team: 

Principal investigators: Drs. Gerald Pfeffer, Alexandra King, Kerri Schellenberg, Toshifumi Yokota

Co-applicants: Drs. Kehinde Ametepee, Malcolm King, Jamie N Leckie, Rika Maruyama, Ashley Secundiak

CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces The NMD4C is excited to share that network investigators Drs. Gerald Pfeffer, Alexandra King, Kerri Schellenberg, Toshifumi Yokota and Malcolm King have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces

Read next...

06 - 2026 Basic Research Summer School - EN

NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!

From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages. 

New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada

We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.